They’re all probing the drug shortage problem, each with a different line of inquiry: the Federal Trade Commission and the Health and Human Services Department, House Oversight Committee Democrats, and the bipartisan leadership of the Senate Finance Committee.
Like hapless Jeopardy contestants, Washington policymakers know the answer to many constituents’ misery is to prevent drug shortages, but they are struggling to find the right question.
Is it how to get market intermediaries to take less profit? Is it how to get pharmaceutical companies to manufacture...
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
